A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer
机构：[1]Fifth Med Ctr Chinese PLA Gen Hosp, Beijing, Peoples R China[2]Liaoning Canc Hosp & Inst, Shenyang, Peoples R China[3]Zheijang Canc Hosp, Hangzhou, Peoples R China[4]Sun Yat Sen Univ, Sun Yat sen Mem Hosp, Guangzhou, Peoples R China中山大学附属第二医院[5]Affiliated Canc Hosp Zhengzhou Univ, Henan Canc Hosp, Zhengzhou, Peoples R China河南省肿瘤医院[6]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China[7]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China河北医科大学第四医院外一科临床科室[8]Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Peoples R China江苏省人民医院[9]Weifang Peoples Hosp, Weifang, Peoples R China[10]Linyi Canc Hosp, Linyi, Shandong, Peoples R China[11]Inner Mongolia Med Univ, Affiliated Hosp, Hohhot, Peoples R China[12]Sun Yet sen Univ Canc Ctr, Guangzhou, Peoples R China[13]Anhui Prov Hosp, Hefei, Peoples R China[14]Hebei Univ, Affiliated Hosp, Baoding, Peoples R China河北大学附属医院
第一作者机构：[1]Fifth Med Ctr Chinese PLA Gen Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Jiang Zefei,Sun Tao,Wang Xiaojia,et al.A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):doi:10.1200/JCO.2022.40.16_suppl.1102.
APA：
Jiang, Zefei,Sun, Tao,Wang, Xiaojia,Liu, Qiang,Yan, Min...&Yang, Hua.(2022).A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA：
Jiang, Zefei,et al."A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)
医学